Dana-Farber Cancer Institute
4members, 0followers
A GENE EXPRESSION SIGNATURE THAT REPRESENTS THE ACTIVATION OF THE KRAS ONCOGENE IN HUMAN CELLS
Using gene expression arrays for the comparison of KRAS oncogenic versus wild type expressing human cell lines, the Dana Farber investigators identified a 300-gene expression signature that ...
A NOVEL INTERACTION SITE ON PRO-APOPTOTIC BAX AS A TARGET FOR PHARMACOLOGIC MODULATION OF CELL SURVIVAL AND APOPTOSIS
The invention is directed to methods, kits and compositions for modulating the activity of BCL-2 family polypeptides (e.g., BAX) by targeting a new regulatory site on BCL-2 family proteins.
BIOMARKERS TO IDENTIFY HIV-SPECIFIC T-CELL SUBSETS
The invention provides a method to determine the immune response in an HIV-infected individual by comparing the expression profile of the subject’s HIV-specific T-cells with that of a chronic ...
CHIMERIC FORM OF TRANSMEMBRANE GLYCOPROTEIN, NKG2D, FOR IMMUNOTHERAPY
The invention relates to the use of a chimeric molecule comprising a receptor portion of the transmembrane glycoprotein, NKG2D, and an Fc portion, for immunotherapy for a wide variety of cancers, ...
CONSERVED INFLUENZA VIRUS HEMAGGLUTININ EPITOPE, ANTIBODIES TO THE EPITOPE, AND METHODS OF USE
Dana-Farber scientists discovered a novel and conserved epitope on the stem region of group 1 influenza viruses and described human broad-spectrum neutralizing antibodies that recognize this epitope.
INDUCTION OF ALTERNATIVE APOPTOTIC PATHWAY BY INHIBITION OF CHK1 IN CANCER CELLS HARBORING P53 AND BCL2 MUTATIONS
The Dana-Farber investigators discovered a novel approach to kill cancer cells that are otherwise resistant to conventional therapies due to mutations in pro-apoptotic (p53) or pro-survival (BCL2) ...
METHOD FOR DETECTING AND IMAGING APOPTOSIS
The invention relates to the detection and monitoring of cells undergoing apoptosis or necrosis and to the selective delivery of therapeutic or diagnostic (labeling) agents to these cells using ...
METHOD TO PREDICT RESISTANCE OF CANCER CELLS TO ANTHRACYCLINE CHEMOTHERAPY
The Dana-Farber scientists discovered that the amplification of the human 8q22-23 region in tumors and over-expression of genes residing in that chromosomal region is associated with and predictive ...
METHODS FOR PREDICTING LIKELIHOOD OF RESPONDING TO TREATMENT IN PROSTATE CANCER
These novel biomarkers can help a medical professional evaluate a patient's medical record and assess multiple treatment strategies for clinical intervention of a patient's condition.
MUTEINS OF HYPOXIA INDUCIBLE FACTOR ALPHA AND METHODS OF USE THEREOF
This technology provides a HIF mutein that is more resistant to degradation (as compared to the wild-type protein) under nonhypoxic conditions.
PREDICTING THE RISK OF PROSTATE CANCER MORBIDITY AND MORTALITY
The invention is based on discovery that the number of CAG repeats in the androgen receptor determines the aggressiveness of prostate cancer and the likelihood that a patient of at least about 60 ...
PROLYL HYDROXYLASE INHIBITORS AS RADIATION MITIGATORS AND RADIATION PROTECTORS
Prolyl Hydroxylase (PH) inhibitors form a novel class of therapeutics that can function as radiation mitigators by protecting healthy cells from the cytotoxic effects of ionizing radiation exposure.
RECOMBINANT RETINOBLASTOMA-ASSOCIATED PROTEIN 1, POLYPEPTIDES AND CDNA
The discovery and mechanism of biological function of Retinoblastoma-Associated Protein 1 (RBAP-1/ E2F-1).
ROLE OF ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES IN CUTANEOUS T-CELL LYMPHOMA AND OTHER CANCERS
The therapeutic anti-CCR4 monoclonal antibody not only directly kills the CCR4+ tumor cells, but also helps to overcome the immunosuppressive effect of CCR4+ regulatory T cells.
ROLE OF ANTI-GALECTIN-1 ANTIBODIES IN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS
The present invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD.
SMALL MOLECULE CD4 MIMETICS PREVENT HIV TRANSMISSION INTO HOST CELLS
The present invention provides the compounds that are capable of disrupting HIV entry into the host cells.
STRONG AGONIST INSULIN MIMETOPE USED IN VACCINATION TO PREVENT TYPE 1 DIABETES DEVELOPMENT
The DFCI scientists developed strategy to use specifically modified insulin mimetopes that are stronger agonists than natural ligand to efficiently induce Tregs and prevent diabetes development in ...
STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE
The present invention is directed to compositions, kits and methods utilizing structurally constrained viral peptides.
TARGETING ACTIVATED MET FOR TREATING CANCERS RESISTANT TO ANTI-ERBB THERAPEUTICS
Development of rapid assays (in form of kits) to screen for MET activation in tumors from cancer patients that undergo or will be subject to anti-ErbB therapy, or developed resistance to such ...
Activity
N/A
